Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
She will be responsible in this role for Finance & Controlling, HR Services and IT Management at Romaco Holding
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Subscribe To Our Newsletter & Stay Updated
